Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 7
Submit an article Journal homepage
104
Views
19
CrossRef citations to date
0
Altmetric
Original Article

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

David H. Henry Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, PA, USA
,
Lucio N. Gordan Gainesville Hematology-Oncology Associates, Gainesville, FL, USA
,
Veena Charu Pacific Cancer Medical Center, Anaheim, CA, USA
,
Francois E. Wilhelm Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USACorrespondence[email protected]
,
Denise Williams Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ, USA
,
John Xie Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA
&
Richard C. Woodman Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA
 show all
Pages 1403-1413 | Accepted 17 May 2006, Published online: 13 Jun 2006

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Alberto Grossi, Francesca Balestri & Simone Santini. (2007) Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia. Therapeutics and Clinical Risk Management 3:2, pages 269-275.
Read now

Articles from other publishers (18)

O. E. Kondratieva, M. E. Abramov, G. V. Vyshinskaya, S. L. Gutorov, E. I. Borisova & E. V. Cherniglazova. (2018) The role of erythropoietins in cancer therapy. Medical Council:10, pages 134-139.
Crossref
Carol A. Forbes, Gillian Worthy, Julie Harker, Jos Kleijnen, Lucie Kutikova, Laurent Zelek & Simon Van Belle. (2014) Dose Efficiency of Erythropoiesis-Stimulating Agents for the Treatment of Patients With Chemotherapy-Induced Anemia: A Systematic Review. Clinical Therapeutics 36:4, pages 594-610.e4.
Crossref
Thomy Tonia, Annette Mettler, Nadège Robert, Guido Schwarzer, Jerome Seidenfeld, Olaf Weingart, Chris Hyde, Andreas Engert & Julia Bohlius. (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews.
Crossref
Chris L. Pashos, Kay Larholt, Kimberly A. Fraser, R. Scott McKenzie, Mekré Senbetta & Catherine Tak Piech. (2011) Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Supportive Care in Cancer 20:1, pages 159-165.
Crossref
Matilde Lombardero, Kalman Kovacs & Bernd W. Scheithauer. (2011) Erythropoietin: A Hormone with Multiple Functions. Pathobiology 78:1, pages 41-53.
Crossref
M. Dicato, L. Plawny & M. Diederich. (2010) Anemia in cancer. Annals of Oncology 21, pages vii167-vii172.
Crossref
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, Guido Schwarzer, Sven Trelle, Jerome Seidenfeld, Marcel Zwahlen, Mike J Clarke, Olaf Weingart, Sabine Kluge, Margaret Piper, Maryann Napoli, Dirk Rades, David Steensma, Benjamin Djulbegovic, Martin F Fey, Isabelle Ray-Coquard, Volker Moebus, Gillian Thomas, Michael Untch, Martin Schumacher, Matthias Egger & Andreas Engert. (2009) Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews.
Crossref
John A. Glaspy, Veena Charu, Donghan Luo, Victor Moyo, Marc Kamin & Francois E. Wilhelm. (2009) Initiation of epoetin-α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy. Cancer 115:5, pages 1121-1131.
Crossref
George M. Rodgers*George M. Rodgers. 2009. Supportive Care in Cancer Therapy. Supportive Care in Cancer Therapy 153 163 .
David H. Henry. (2008) Extended-dosing epoetin alfa for chemotherapy-induced anemia: focus on elderly breast and colorectal cancer patients. Community Oncology 5:6, pages 310-321.
Crossref
Harminder Sikand, Adam Decter, Tina Greco, Sue H Watson, Yoon Jun KangSamir H ModyCatherine Tak PiechMei Sheng DuhAyesha Naeem. (2016) Cost Analytic Model to Determine the Least Costly Inpatient Erythropoiesis Stimulating Therapy Regimen. Annals of Pharmacotherapy 42:1, pages 16-23.
Crossref
M. R. Nowrousian. 2008. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology 449 508 .
Raymond J. Muller & David Baribeault. (2007) Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia. American Journal of Health-System Pharmacy 64:24, pages 2547-2556.
Crossref
Vernon P. Montoya, John Xie, Denise Williams, Richard C. Woodman & Francois E. Wilhelm. (2007) An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Supportive Care in Cancer 15:12, pages 1385-1392.
Crossref
Stephanie A. Gregory, John Xie, Tomek Szczudlo, Denise Williams, Richard C. Woodman & Francois E. Wilhelm. (2007) An Extended Dosing Regimen of Epoetin Alfa 60,000 Units Every 2 Weeks in Anemic Patients with Cancer Receiving Chemotherapy. Supportive Cancer Therapy 4:4, pages 225-232.
Crossref
David H. Henry. (2007) Epoetin Alfa Treatment for Patients with Chemotherapy-Induced Anemia. Supportive Cancer Therapy 4:2, pages 78-91.
Crossref
David H Henry. (2007) Guidelines and Recommendations for the Management of Anaemia in Patients with Lymphoid Malignancies. Drugs 67:2, pages 175-194.
Crossref
Prabhakara K. Reddy, Denise Williams & Francois E. Wilhelm. (2006) An Open-Label Pilot Study to Evaluate a Flexible Dosing Regimen of Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: 60,000 Units Weekly Followed by 60,000 Units Every 2 Weeks. Supportive Cancer Therapy 4:1, pages 56-62.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.